Von Willebrand-Related Test Abnormalities
Low value for von Willebrand factor (vWF) and/or ristocetin cofactor (RCoF) or values in the low end of these normal ranges with a history of mild bleeding affecting males and females in the family suggest von Willebrand disease (vWD).
vWD could be type 1, 2A, 2B, 2M, 2N, or 3.
A person with blood type O who does not have vWD, since persons with blood type O have a mean vWF of only about 75% of normal.
Suggested Additional Lab Testing
RCoF, vWF, and factor VIII level (factor VIII level often decreases along with the other 2).
In type 1 vWD, RCoF and vWF are suppressed approximately equally and mildly abnormal.
In type 2, vWF is typically greater than or equal to 15% greater than RCoF, and the values for both are in the 20% range or lower.
In type 3, both of these values approximate 0.
Fibrinogen is an important measurement, because it is an acute phase reactant.
Fibrinogen elevation suggests that RCoF and vWF levels do not represent the patient's true baseline values and that a repeat test at a later time is necessary.
Obtain blood type: mean value for vWF varies with blood type.
VWF multimer analysis by agarose gel electrophoresis and Western blotting is useful when there is a high likelihood of non-type 1 vWD.
Desmopressin (DDAVP) stimulation test (except if the patient has type 2B or platelet type vWD) may be useful to determine if DDAVP can be used clinically to treat vWD.
In the test, samples for RCoF and vWF are taken before DDAVP administration and then again 60 minutes after completion of a 30-minute infusion of DDAVP.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Next Article in LabMed
Neurology Advisor Articles
- Ajovy Injection Approved for Migraine Prevention in Adults
- Higher Levels of Cholesterol May Protect Men From Parkinson Disease
- Chronic Pain May Be Contributor to Suicide
- FDA Approves Tiglutik for the Treatment of Amyotrophic Lateral Sclerosis
- Few With Acute Migraine Take Triptans, Many Discontinue the Drug
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- New 15-Item Dyspnea-ALS-Score Assesses Dyspnea in ALS
- CDC: About One in Five U.S. Adults Have Chronic Pain
- Fingolimod Cuts Multiple Sclerosis Relapses in Pediatric Patients
- Gains in Insurance Coverage Seen for Lesbian, Gay, Bisexual Adults
- Brivaracetam Effective for Reducing Seizures in Patients with Epileptic Encephalopathies